Literature DB >> 22692653

Post-marketing observational trials and catastrophic health expenditure.

John S Yudkin1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22692653     DOI： 10.1136/bmj.e3987

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Authors:  Chantal Mathieu; Claes-Göran Ostenson; Stephan Matthaei; Matthew Reaney; Thure Krarup; Bruno Guerci; Jacek Kiljański; Carole Salaun-Martin; Hélène Sapin; Michael Theodorakis
Journal:  Diabetes Ther       Date:  2013-09-10       Impact factor: 2.945

2.  Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Authors:  Urpo Kiiskinen; Stephan Matthaei; Matthew Reaney; Chantal Mathieu; Claes-Göran Ostenson; Thure Krarup; Michael Theodorakis; Jacek Kiljański; Carole Salaun-Martin; Hélène Sapin; Bruno Guerci
Journal:  Clinicoecon Outcomes Res       Date:  2013-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.